uniQure (QURE)
(Real Time Quote from BATS)
$13.91 USD
+0.22 (1.57%)
Updated Aug 4, 2025 03:04 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QURE 13.91 +0.22(1.57%)
Will QURE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QURE
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Other News for QURE
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Biotech stocks rise following Prasad exit from FDA
Biotech stocks rise following Prasad exit from FDA
uniQure (QURE) Price Target Trimmed by Cantor Fitzgerald
uniQure price target lowered by $11 at Cantor Fitzgerald, here's why